Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Edoxaban (Lixiana) (DU-176) 是一种选择性的,口服有效的 factor Xa (FXa)抑制剂。Edoxaban 对游离 FXa 和凝血酶原的 Ki 分别为 0.561 nM 和 2.98 nM。Edoxaban 是一种抗凝剂,可用于预防中风。Edoxaban 还是一种凝血酶和凝血因子 IXaβ (FIXa) 的弱抑制剂,Ki 值分别为 6.00 μM 和 41.7 μM,对 FXa 的选择性超过 10000 倍。由于具有抗血栓形成的特性,Edoxaban 可用于预防血栓栓塞性疾病的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 198 | 现货 | ||
5 mg | ¥ 413 | 现货 | ||
10 mg | ¥ 579 | 现货 | ||
25 mg | ¥ 871 | 现货 | ||
50 mg | ¥ 997 | 现货 | ||
100 mg | ¥ 1,479 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 455 | 现货 |
产品描述 | Edoxaban (Lixiana) (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with K i s of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and is able to be used for stroke prevention. Edoxaban is a also weak inhibitor of thrombin and factor IXaβ (FIXa), with K i s of 6.00 μM and 41.7 μM, respectively, exhibits >10 000-fold selectivity for FXa. Edoxaban has antithrombotic properties and is potential for thromboembolic diseases treatment [1] [2] [3]. |
体外活性 | Edoxaban (DU-176b) also inhibits rat, cynomolgus monkey and rabbit FXa with K i values of 6.90 nM, 0.715 nM and 0.457 nM, respectively [1]. Prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT) of human plasma are prolonged by Edoxaban (DU-176b) in a concentration-dependent way, doubling PT and APTT at 0.256 and 0.508 μM, respectively. The double clotting time (CT2) for TT, however, was much higher (4.95 μM), reflecting its anti-thrombin activity. Thrombin-induced platelet aggregation is inhibited by a high concentration of Edoxaban (DU-176b) (IC 50 : 2.90 μM), reflecting its weak anti-thrombin activity [1]. Edoxaban is minimally metabolized (,4%) by the cytochrome P450 system (CYP3A4) and is a substrate for P-glycoprotein [2]. |
体内活性 | Edoxaban (DU-176b; 0.5-12.5 mg/kg; oral administration; Wistar rats) inhibits thrombus formation in rat thrombosis models in a dose-dependent manner [1]. Animal Model: Wistar rats (210-240 g) with venous stasis thrombosis model [1] Dosage: 0.5 mg/kg, 2.5 mg/kg, 12.5 mg/kg Administration: Oral administration Result: Dose-dependently inhibited thrombus formation in rat thrombosis models. |
别名 | Lixiana, 依杜沙班 |
分子量 | 548.06 |
分子式 | C24H30ClN7O4S |
CAS No. | 480449-70-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 130 mM
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8246 mL | 9.1231 mL | 18.2462 mL | 45.6154 mL |
5 mM | 0.3649 mL | 1.8246 mL | 3.6492 mL | 9.1231 mL | |
10 mM | 0.1825 mL | 0.9123 mL | 1.8246 mL | 4.5615 mL | |
20 mM | 0.0912 mL | 0.4562 mL | 0.9123 mL | 2.2808 mL | |
50 mM | 0.0365 mL | 0.1825 mL | 0.3649 mL | 0.9123 mL | |
100 mM | 0.0182 mL | 0.0912 mL | 0.1825 mL | 0.4562 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Edoxaban 480449-70-5 Metabolism Proteases/Proteasome Factor Xa Thrombin Lixiana 依杜沙班 Inhibitor inhibitor inhibit